Missing Script

Get updates

Evidence Explorer / MS-N211 / Unsupported cure claims and safety / Appraised November 2, 2026

Insulin potentiation therapy (IPT) uses insulin before reduced-dose chemotherapy on the theory that insulin makes tumors more sensitive to treatment. Human evidence is sparse. One very small randomized breast-cancer trial suggested less short-term tumor growth with insulin plus methotrexate, but it did not establish response, survival or equivalence to standard chemotherapy.

Evidence at a glance

  • Population: 30 women with metastatic breast cancer resistant to prior chemotherapy and hormonal therapy.
  • Design: randomized into three groups of 10 for two 21-day courses.
  • Comparator: insulin plus methotrexate, methotrexate alone, or insulin alone.
  • Finding: stable disease was more frequent and median tumor-size increase was smaller with the combination; survival and durable benefit were not established.
  • Evidence label: very preliminary, inconclusive evidence; insufficient to support IPT or reduced-dose chemotherapy.

What was studied

The 2004 report measured target lesions using RECIST after two short courses. Most participants receiving either methotrexate alone or insulin alone had progressive disease, while stable disease occurred more often with insulin plus methotrexate. The abstract does not provide confidence intervals, allocation details, durable follow-up or overall-survival results.

Other published IPT reports are small and methodologically weak. A 2019 review from National Cancer Institute authors concluded that evidence remained insufficient. Registration, testimonials or a metabolic rationale are not proof of efficacy.

What this evidence cannot establish

The study does not show that insulin allows chemotherapy to be safely or effectively reduced below evidence-based doses. Stable disease over a short interval is not the same as tumor response, longer progression-free survival or longer life.

The formulation, timing and chemotherapy doses sold under the IPT label vary. Results from one methotrexate study cannot be generalized to other drugs, cancers or commercial protocols.

Practical safety context

Giving insulin can cause severe hypoglycemia, confusion, seizures, loss of consciousness or death. Reducing chemotherapy may also lower the chance of cancer control. These risks require licensed oncology oversight and emergency capability.

Claims that insulin selectively feeds or opens cancer cells oversimplify tumor biology. IPT should not replace a regimen with established dose, schedule and outcome evidence.

Questions for the care team

  • What evidence supports the exact cancer, drug, dose and schedule being proposed?
  • How would hypoglycemia be prevented, monitored and treated?
  • What is lost by reducing the chemotherapy dose, and is there a validated alternative?

Sources

Source note: The randomized trial abstract, PubMed metadata, a small full-text report and an NCI-authored review were checked. Full-text access to the randomized trial was not available, so unreported allocation, adverse-event, funding and conflict details remain not verified. No correction or retraction was identified on November 2, 2026.

This record is educational. Insulin and chemotherapy are high-risk medicines; do not alter cancer-treatment doses or schedules outside qualified oncology care.